Evaluation of Anti Epstein-Barr Virus Early Antigen (Igg) Antibody Serum Level in Neuromyelitis Optica Spectrum Disorder Patients

Document Type : Original Article(s)

Authors

1 Professor, Department of Pathology, School of Medicine, Infectious Diseases and Tropical Medicine Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

2 Professor of Neurology, Department of Neurology, School of Medicine, Neurosciences Research Center Kashani Hospital, Isfahan University of Medical Sciences, Isfahan, Iran

3 School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

4 Clinical Instructor and Family Physician Associate, Faculty of Medicine, University of British Columbia, Canada

10.48305/jims.v43.i820.0722

Abstract

Background: Epstein-Barr virus (EBV) infection has been recognized as the most important environmental factor in the development of Multiple Sclerosis. The role of EBV as a risk factor in neuromyelitis optica spectrum disorder (NMOSD) is under discussion. The aim of this study is to evaluate the association of anti-EBV early antigen (IgG) antibody serum levels with NMOSD compared with healthy controls.
Methods: In this case-control study, we measured levels of serum antibody against early EBV antigen (EA) IgG in 40 patients with NMOSD and 43 healthy controls with CHORUS kits (based on Enzyme Linked Immunosorbent Assay; ELISA). The independent t-test, The Chi-square test, a linear regression model were applied.
Findings: No association was observed between NMOSD, sex, age and BMI and the serum level of anti EBV Early antigen (IgG) levels. The strong association between EBV and MS as a key environmental risk factor was not observed between EBV and NMOSD.
Conclusion: In conclusion, our results showed that there is no significant difference in the serum levels of anti-EA IgG antibody between 40 NMOSD patients and 43 healthy controls. Further studies in this field are recommended.

Highlights

Azar Baradaran: Google Scholar 

Vahid Shaygannejad: Google Scholar

Behzad Azarmju: Google Scholar 

Keywords

Main Subjects

References

  1. Jarius S, Wildemann B, Paul F. Neuromyelitis optica: clinical features, immunopathogenesis and treatment. Clin Exp Immunol 2014; 176(2): 149-64.
  2. Wildemann B, Jarius S. The expanding range of autoimmune disorders of the nervous system. Lancet Neurol 2013; 12(1): 22-4.
  3. Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG. The spectrum of neuromyelitis optica. Lancet Neurol 2007; 6(9): 805-15.
  4. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33(11): 1444-52.
  5. Cossburn M, Tackley G, Baker K, Ingram G, Burtonwood M, Malik G, et al. The prevalence of neuromyelitis optica in South East Wales. Eur J Neurol 2012; 19(4): 655-9.
  6. Yamakawa K, Kuroda H, Fujihara K, Sato S, Nakashima I, Takeda A, et al. Familial neuromyelitis optica (Devic’s syndrome) with late onset in Japan. Neurology 2000; 55(2): 318-20.
  7. Matiello M, Kim H, Kim W, Brum DG, Barreira AA, Kingsbury D, et al. Familial neuromyelitis optica. Neurology 2010; 75(4): 310-5.
  8. Levinson JB, Alvarez MR, Koci K, Feoktistov A, McFarlane IM. Epstein-Barr virus infection in a patient with neuromyelitis optica spectrum disorder and sjögren’s syndrome: A case report and review of literature. Hemoglobin (g/dL). 2018; 12: 12.0-6.0.
  9. Ascherio A, Munger KL. Environmental risk factors for multiple sclerosis. Part I: the role of infection. Ann Neurol 2007; 61(4): 288-99.
  10. Koga M, Takahashi T, Kawai M, Fujihara K, Kanda T. A serological analysis of viral and bacterial infections associated with neuromyelitis optica. J Neurol Sci 2011; 300(1-2): 19-22.
  11. Harley JB, Chen X, Pujato M, Miller D, Maddox A, Forney C, et al. Transcription factors operate across disease loci, with EBNA2 implicated in autoimmunity. Nat Genet 2018; 50(5): 699-707.
  12. Lossius A, Johansen JN, Torkildsen Ø, Vartdal F, Holmøy T. Epstein-Barr virus in systemic lupus erythematosus, rheumatoid arthritis and multiple sclerosis—association and causation. Viruses 2012; 4(12): 3701-30.
  13. Cohen JI. Epstein–Barr virus infection. N Engl J Med 2000; 343(7): 481-92.
  14. Tselis AC. Epstein-Barr virus infections of the nervous system. Handb Clin Neurol 2014; 123: 285-305.
  15. Klutts JS, Ford BA, Perez NR, Gronowski AM. Evidence-based approach for interpretation of Epstein-Barr virus serological patterns. J Clin Microbiol 2009; 47(10): 3204-10.
  16. Masuda S, Mori M, Arai K, Uzawa A, Muto M, Uchida T, et al. Epstein-Barr virus persistence and reactivation in neuromyelitis optica. J Neurol Neurosurg Psychiatry 2015; 86(10): 1137-42.
  17. Simon KC, Schmidt H, Loud S, Ascherio A. Risk factors for multiple sclerosis, neuromyelitis optica and transverse myelitis. Mult Scler 2015; 21(6): 703-9.
  18. Yoshimura S, Isobe N, Matsushita T, Yonekawa T, Masaki K, Sato S, et al. Distinct genetic and infectious profiles in Japanese neuromyelitis optica patients according to anti-aquaporin 4 antibody status. J Neurol Neurosurg Psychiatry 2013; 84(1): 29-34.
Journal of Isfahan Medical School
Volume 43, Issue 820
4th Week, August
July and August 2025
Pages 722-727

Files

History

  • Receive Date: 29 April 2025
  • Accept Date: 19 July 2025

Share

How to cite

Statistics